Welcome Reception

Bay Lawn 

Breakfast & Registration 

 

Welcome & introduction
Gareth Morgan & Ola Landgren 

Session 1: Genomics and epigenomics 2025
Chairs: Gareth Morgan & Leif Bergsagel

• The genetic basis for racial disparity in MM: Kylee MacLachlan 
• NSD2 mechanism of action: Yubao Wang 
• The t(4:14) and apoptosis: Lawrence Boise 
• Epigenetic data from CoMMpass: Benjamin Barwick 
• An all-genetic classifier of MM and IRMMA: Francesco Maura  
• Bringing genomics to the clinic: Sarah Gooding  

 

Panel discussion: Using genomic targets in MM

Break

Session 2: Resistance mechanisms
Chairs: Benjamin Diamond & Niels Weinhold

• PHF19 a tudor domain protein and HRMM: Brian Walker
• Tumor intrinsic resistance mechanisms to myeloma CAR–T and bispecifics: Michael Durante 
• Lenalidomide resistance: Charlotte Pawlyn
• Transcriptional resistance to IMiD: Leif Bergsagel
• Using scRNAseq to define drug resistance: (TBC)

 

Panel discussion: addressing drug resistance

Session 3: Biological models and single cell analyses                                                               
Chairs: Charlotte Pawlyn & Felipe Prósper

• Sc analyses of high-risk myeloma: Robert Orlowski 
• The Vk*MYC mouse model: Marta Chesi
• Pre-clinical models of MM: José Ángel Martínez–Climent
• Spatial transcriptomics: Niels Weinhold
• Epigenetic drivers of disease progression: Felipe Prósper 
• Microenvironment-mediated resistance to treatment: Madhav Dhodapkar

 

Panel discussion: future strategies for myeloma management

Lunch

Session 4: Update on MRD as a clinical endpoint
Chairs:  Ola Landgren

 

Panel discussion

Session 5: Clinical trial updates
Chairs: Jesus San Miguel & Rafael Fonseca

• Moving clinical trials forward towards a cure: Saad Usmani
• Strategies for the clinical evaluation of bispecifics: Ola Landgren
• Belantamab mafodotin update: Rafael Fonseca 
• Isatuximab combinations: Thomas Martin 
• Trials in Spain: Jesus SanMiguel 
• Daratumamab – recent combination data: Dickran Kazandjian

 

Panel discussion: questions for clinical trials

Break

Session 6: MMRF Update
Chairs: George Mulligan & Hearn Cho

• The HORIZON Adaptive trial platform: (TBC)
• Translational studies of the MyDrug trial MEKi arm: (TBC)
• Tumor and microenvironment insights from Immune Atlas: (TBC)

 

Panel Discussion

Closing remarks 

Welcome and Introductions

Keynote Lecture 

Chair: Niels Weinhold

 

The spatio-temporal evolution of multiple myeloma: Leo Rasche

 

Panel discussion 

Session 7:  Novel Targets
Chairs: Faith Davies                                                                                

• Allogeneic BCMA-targeting CAR–T cells in r/r MM: Sham Mailankody  
• Targeting RAS: Faith Davies 
• SWI-SNF as a target in MM: Ryan Young
• Membrane markers as targets for the t (4:14): Arun Wita 
• CL 131 (Iopofosine I-131) in RRMM: Sikander Ailawadhi

 

Panel discussion: developing novel targets for the clinic

Break

Session 8: Debates in MM
Chairs: Ola Landgren & Nizar Bahlis

Roundtable: Saad Usmani, Rafael Fonseca, Keith Stewart

 

1. Should use CAR-T at first relapse

For: Rafael Fonseca       

Against: Keith Stewart

 

2. Vaccination is important strategy

For: David Avigan

Against: Saad Usmani

 

3. Combinations of Bispecifics and CAR-T vs new designs

(TBC) vs Eric Smith 

 

4. Short– vs long–duration therapy with bispecifics     

 

Roundtable panel discussion

Session 9: Optimizing T-Cell Engaging therapy in the clinic: data session

Part 1: Bispecifics 

Chairs: Yi Lin

• Elranatamab, Tec, Linvo: Nizar Bahlis 
• Teclistamab: Saad Usmani
• Talquetamab: (TBC)
• Linvoseltamab: Madhav V. Dhodapkar  
• Durcabtagene autoleuce: (TBC) 
• Optimizing BCMA as a target: (TBC)   
• Real world data: (TBC) 

Panel discussion

Lunch

Part 2: CAR-T

Chairs: Adam Cohen & Ciara Freeman

• State of the Art CAR-T in MM: Fred Locke 
• Update on current use: Adam Cohen 
• Anito-cel: Matthew J. Frigault 
• P-BCMA-ALLO1: (TBC) 
• CB-011: allogeneic anti-BCMA CAR-T: Adrianna Rossi
• Clinical management of CAR-T agents and their use in older adults: Ciara Freeman 
• Innovative CAR-T designs and targets: Yi Lin 
• ADC in the MM: Hans Lee 

Panel discussion: Optimizing the use of Bispecifics and CAR-T in the clinic  

Summary & closing remarks of iwMyeloma

Gareth Morgan & Ola Landgren

iwMyeloma Scientific Committee: 

Gareth Morgan (Co-Chair) USA, Ola Landgren (Co-Chair) USA
Ken Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Sagar Lonial USA, Maria Victoria Mateos Spain, Jesus San Miguel Spain, Pieter Sonneveld NL, Keith Stewart Canada